Crossmark

A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice

Crossref DOI link: https://doi.org/10.1186/s12985-018-1089-1

Published Online: 2018-11-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Pengcheng

Yan, Jianghong

Wu, Weicheng

Tao, Xiaoyan

Lu, Xuexin

Liu, Shuqing

Zhu, Wuyang
Funding

Funding for this research was provided by:

the National Program on Key Research Project of China (2016YFD0500400)

The National Natural Science Foundation of China (31500152)

China Mega-Project for Infectious Disease (2017ZX10104001-004-001)

National Key R&D Program of China (2017YFC1200503)

National Science and Technology Major Project (2018ZX10201002)
License Information

Text and Data Mining valid from 2018-11-13
More Information

Article History

Received: 12 March 2018

Accepted: 1 November 2018

First Online: 13 November 2018

Ethics approval and consent to participate

: The program for immunization of HDCV combined with CpG ODN was approved (approval NO. 201510140028) by the Ethical Committee of the National Institute of Viral Disease Control and Prevention, China CDC. Animal care and use protocol in this study abided “The Guidance on Treating Experimental Animals” which promulgated by the ministry of science and technology of China. No non-human primates were used in this study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.